Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cubist

- PMLiVE

Merck strengthens KRAS stake with Taiho and Astex partnership

Partner companies could gain $2.5bn in milestone payments

- PMLiVE

Lynparza cleared for first-line ovarian cancer use in China

Continues to cement lead in PARP inhibitor category

- PMLiVE

Merck’s Keytruda significantly extends life in some prostate cancer patients

Pivotal study identifies group of 'super responders'

- PMLiVE

Merck’s Keytruda picks up third approval for NSCLC in China

New indication as a first-line treatment in combination with chemotherapy

- PMLiVE

MSD’s Keytruda scores another EU okay, in head and neck cancer

First anti-PD-1 drug to improve overall survival in first-line setting

- PMLiVE

MSD hangs ‘for sale’ sign on French facility, shedding 207 staff

Job losses will be across manufacturing and R&D divisions

- PMLiVE

Merck wins CHMP recommendation for Ebola vaccine

Has also been granted priority review by FDA

- PMLiVE

Women living with cancer feel stigmatized, says new report

Highlights need for increased education, awareness and support

- PMLiVE

FDA starts speedy review of Merck’s Ebola vaccine

First company to file for approval in the US

- PMLiVE

MSD’s Keytruda catches up in kidney cancer

Combination therapy approved in EU for all risk groups

- PMLiVE

MSD taps Austria’s Themis to bolster vaccine pipeline

First big pharma partner for measles virus vector platform

- PMLiVE

Keytruda now available for untreated metastatic lung cancer patients via Cancer Drugs Fund

Proves continuing dominance in this indication

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links